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Abstract The mitogen-activated protein kinase-activated
protein kinase MK5 is ubiquitously expressed in verte-
brates and is implicated in cell proliferation, cytoskeletal
remodeling, and anxiety behavior. This makes MK5
an attractive drug target. We tested several diterpenoid
alkaloids for their ability to suppress MK5 kinase activity.
We identiﬁed noroxoaconitine as an ATP competitor
that inhibited the catalytic activity of MK5 in vitro (IC50 =
37.5 lM; Ki = 0.675 lM) and prevented PKA-induced
nuclear export of MK5, a process that depends on kinase
active MK5. MK5 is closely related to MK2 and MK3, and
noroxoaconitine inhibited MK3- and MK5- but not MK2-
mediated phosphorylation of the common substrate Hsp27.
Molecular docking of noroxoaconitine into the ATP bind-
ing sites indicated that noroxoaconitine binds more
strongly to MK5 than to MK3. Noroxoaconitine and
derivatives may help in elucidating the precise biological
functions of MK5 and may prove to have therapeutic
values.
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kinase
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RMSD Root mean squared
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Introduction
Mitogen-activated protein kinase (MAPK) signal trans-
duction pathways are activated by many different stimuli,
and they regulate diverse processes ranging from prolifer-
ation and differentiation to apoptosis. To date, seven
distinct MAPKs pathways have been discovered in mam-
malian cells, including: extracellular signal-regulated
kinases (ERK1 and ERK2); c-Jun N-terminal kinases
(JNK1, JNK2 and JNK3); p38
MAPK (p38a, p38b, p38c and
p38d); ERK3 and ERK4; ERK5; and ERK7 and ERK8
[1–9]. The typical MAPKs family consists of at least three-
tiered cascades: upstream MAPK kinase kinase (MAP3K,
MEKK or MKKK), a MAPK kinase (MAP2K, MEK or
MKK), and a downstream MAPK. Each MAPK can
phosphorylate a variety of substrates, including protein
kinases referred to as MAPK-activated protein kinases
(MAPKAPKs or MKs) [3, 5, 10–14]. The human MK
family comprises 11 different members: 4 p90 ribosomal
S6 kinases (RSK1-4), 2 mitogen- and stress-activated
protein kinases (MSK1 and MSK2), 2 MAPK-interacting
kinases (MNK1 and MNK2), and 3 MAPK-activated pro-
tein kinases (MK2, MK3 and MK5) [15]. According to
their sequence, all MKs can be classiﬁed into ﬁve sub-
groups: RSKs, MSKs, MNKs, MK2 and MK3, and MK5
[2, 16–20].
MK5 or the human analogue p38-regulated/activated
kinase, PRAK, was originally discovered as a sequence tag
by the searching of sequences homologous to MK2
[21, 22]. Their catalytic domain displays 48% amino acid
identity and their overall sequence identity is 42%. MK3,
which possesses 75% overall identity with MK2, is 41%
identical with MK5. All three proteins seem to be ubiqui-
tously expressed [16, 23], but the expression level and
activity of MK2 are signiﬁcantly higher than MK3 in the
cells and tissues examined [17]. The expression level and
activity of MK2 and MK5 in different cells has not been
compared. MK2, MK3, and MK5 exert different biological
roles as is reﬂected by their substrate speciﬁcity and dif-
ferences in phenotypes of knock-out mice [15, 24–26].
Nevertheless, they may participate in common func-
tions such as F-actin remodeling (MK2 and MK5)
and stimulation of tumor necrosis factor synthesis and
p38
MAPK stabilization (MK2 and MK3) [26]. Studies in
MK5-deﬁcient mouse models and cells have demonstrated
that depletion promoted oncogenic transformation by c-Ha-
RAS and facilitated dimethylbenzanthrance-induced skin
carcinogenesis [24]. Furthermore, MK5 overexpression
inhibited proliferation of NIH3T3 cells [27]. MK5 also
seems to be involved in PKA-induced F-actin rearrange-
ment and cell migration through Hsp27 phosphorylation,
which is suppressed by 14-3-3e [28–30]. Moreover, trans-
genic mice expressing constitutive active MK5 displayed
anxiety-related traits and locomotor differences compared
to wild-type littermates, suggesting the involvement of
MK5 in anxiety behavior [31]. In spite of these described
functions, the exact biological role of MK5 is still
incompletely understood because MK5 knock-out mice do
not display any obvious phenotype under normal condi-
tions [24, 25].
The physiological function of protein kinases can be
investigated by multiple approaches using targeted gene
knock-out and knock-in animal models, RNA interference,
overexpression of constitutive active or dominant negative
mutants, and by the use of speciﬁc inhibitors (reviewed in
[4, 32]). In recent years, there has been a globally
increasing interest in herbal compounds because of their
beneﬁcial effect on human health, but also as potential
speciﬁc protein kinase inhibitors [33, 34]. One group of
them, the diterpenoid alkaloids (DAs), has been tested, but
due to their toxic nature there are very few reports about
their pharmacological effects. Tyrosinase inhibition and
structure–activity relationship (SAR) of 15 DAs, with
lycoctonine skeleton, and semisynthetic derivatives have
been reported [35]. Some of the DAs were also reported to
be active chemotherapeutic agents by inhibiting American
trypanosomiasis [36]. To date, no speciﬁc MK5 inhibitors
have been reported. This prompted us to test several DAs
for their ability to suppress enzymatic activity of MK5.
One of them, noroxoaconitine, speciﬁcally inhibited MK5
but not MK2 with an IC50 = 37.5 lM. This compound
may therefore be a valuable tool in MK5 studies.
Materials and methods
Chemicals
The DAs were generously provided by Prof. M. Sultan-
khudzaev, Uzbek National Academy of Science, Tashkent,
Uzbekistan. The compounds are HPLC grade pure and
structures have been conﬁrmed by different NMR tech-
niques. The compounds were earlier cited elsewhere [37],
and the structures are shown in Fig. 7 (see below, under
‘‘Docking of inhibitors at the ATP binding site of MK5’’).
Compounds 1–8 and 12–14 are natural alkaloids, while
compounds 9–11 are semi-synthetic derivatives [37 and
290 S. Kostenko et al.references therein]. Forskolin was purchased from Sigma-
Aldrich (St. Louis, MO, USA),
32P c-ATP was obtained
from Perkin Elmer (Waltham, MA, USA), while recom-
binant MK2, MK3, and MK5 were from Invitrogen
(Carlsbad, CA, USA). The expression plasmid encoding
EGFP-MK5 fusion protein has been previously described
[29]. Recombinant Hsp27 was purchased from Signal
Chem (Richmond, BC, Canada). The MK5 substrate pep-
tide PRAKtide (KKLRRTLSVA) was purchased from
Millipore (Billerica, MA, USA).
Biological studies
Screening and kinase activity
Screening of the DAs for inhibition of MK5 enzymatic
activity was performed as follows. MK5 kinase activity
was monitored against 30 lM PRAKtide substrate peptide
at 30C for 20 min in 50 ll of buffer containing 40 mM
Tris–Cl, pH 7.5, 0.4 mg/ml BSA, 15 mM MgCl2, 0.1 mM
cold ATP, and 1 lCi of [c-
32P]ATP (3,000 Ci/mmol),
recombinant MK5 (45 ng per assay) in the presence or
absence of DAs. The initial screening was done in the
presence of 2 mM DA. Following incubation, 15-ll ali-
quots were spotted onto phosphocellulose disks (Millipore)
and washed extensively with 1% phosphoric acid before
measurement of radioactive incorporation by scintillation
counting. Activity was determined as proposed by Mett
et al. [38] where the average of counts in the presence of
compounds were calculated, then negative controls (C
-)
(reaction in the absent of active MK5) were subtracted
from these values and divided by the positive control (C
?)
(reaction in the present of active MK5, but without com-
pounds) minus the negative control, resulting in kinase
activity.
Kinase activity ð%Þ¼
100 ðavcpmcompoundÞ ðavC Þ
ð avCþÞ ðav C Þ
ð1Þ
Percentage of inhibition was calculated from kinase
activity as follows:
Inhibition ð%Þ¼100   Kinase activityð%Þð 2Þ
In vitro phosphorylation of Hsp27 by MK2, MK3, and
MK5 was performed as previously described [28]. The
pSer-78 Hsp27 speciﬁc antibodies were purchased from
Millipore (cat. no. #04-447).
Kinetic studies
Enzyme inhibition reactions were performed to study the
kinetic trends and ATP competitions of the active com-
pounds (11 and 8). The biochemical method was similar to
the screening described above. The difference was that
multiple inhibitor (0.025, 0.125, 0.25, 1.25, and 2.5 mM)
and ATP concentrations (1, 8, 16, and 32 mM) were used.
The kinetic data (Vmax, Km) were analyzed using
Enzyme Kinetic
TM module of SigmaPlot
TM version 10,
integrated with SigmaStat
TM. The Ki values were deter-
mined from IC50 of the inhibitors values using the Cheng-
Prusoff relationship [39–41].
Ki ¼ IC50=ð1 þ S=KmÞð 3Þ
Cell culture and transfection
PC12 cells, a kind gift from Dr. Jaakko Saraste (University
of Bergen, Norway), were maintained in F-12K Medium
(Kaighn’s Modiﬁcation of Ham’s F-12 Medium) supple-
mented with 2 mM L-glutamine, 1.5 g/l sodium bicarbo-
nate, 15% Horse serum (Gibco) and 2.5% fetal calf serum,
penicillin (110 U/ml) and streptomycin (100 lg/ml). Cells
were transfected using the Nucleofection kit (Amaxa)
according to the manufacturer’s instructions. The EGFP-
MK5expressionplasmidhasbeenpreviouslydescribed[42].
TheplasmidthatencodestheEGFP-NESfusionproteinwith
the NES motif of the Rev protein of human immunodeﬁ-
ciency was constructed by cloning the complementary
oligonucleotides 50-CCG GAG ACG CTC TAC CAC CGC
TTG AGA GAC TTA CTC TTG ACC GAG CT-30 and
50-CGG TCA AGA GTA AGT CTC TCA AGC GGT GGT
AGA GCG TCT-30 into the BspEI/SacI sites of pEGFP-C1
(Clontech, Mountain View, CA, USA).
Confocal microscopy
Cells were ﬁxed for 10 min with 4% formaldehyde. Then
cells were washed with PBS and examined using a con-
focal laser-scanning Zeiss LSM 510 META microscope.
Several hundred cells were monitored and representative
pictures are presented.
Computational biology
Homology modeling of MK5
The X-ray crystal structure of MK5 is not known. A model
of MK5 was therefore constructed by homology with
MK2 using the traditional homology modeling approach.
The PDB co-ordinates of MK2 (chain A, 2OZA [43])
was obtained from the Protein Databank (PDB, http://
www.pdb.org) and used as template for constructing the
MK5 model based on the amino acid sequence of MK5
[22]. The model was built using the ICM
TM Bioinformatics
module. The ICM program constructs the molecular model
by homology from core sections deﬁned by the average of
Ca atom positions in conserved regions.
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The model quality check was performed using Structural
Analysis and Veriﬁcation Server (SAVS, http://nihserver.
mbi.ucla.edu/SAVS/). PROCHECK [44, 45], WHAT_
CHECK, ERRAT [46], VERIFY_3D [47, 48], and
PROVE, were used to calculate quality factors of both the
template (2OZA) and the generated 3D model of MK5. The
total, local, burial and contact energies of the predicted
models were calculated using predicted structure quality
score (PSQS) (http://www1.jcsg.org/psqs)[ 49–52].
RMSD calculations
The 3D structures of 2OZA and the MK5 model were
superimposed and their RMSD (root mean squared devia-
tion) between backbone Ca atoms value was calculated
utilizing DaliLite (http://www.ebi.ac.uk/DaliLite)[ 53]i n
order to compare their overall 3D structures and active site
architecture.
Docking
Compounds 8 and 11 were docked into the MK5, while
compound 11 was also docked into the X-ray structures of
MK2 and MK3 [54]. The docking studies of the com-
pounds were performed as previously described [55]. The
Internal Coordinate Mechanics (ICM) program from Mol-
soft (http://www.molsoft.com/) was used for the docking
studies.
Compounds 8 and 11 were docked into the predicted
binding site of MK5, which corresponds to the ATP
binding site of MK2 and MK3, while compound 11 was
also docked into the ATP binding site of MK2 and MK3.
The best docking conformations were selected based on
docking energies, RMSD of ligand from initial ligand
conformation, and similarities with ATP binding in known
X-ray crystal structures (2PHK [56] and 2JBO [57]). The
potent MK5 inhibitor 2-(2-quinolin-3-ylpyridin-4-yl)-
1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one was also
docked into the predicted binding site of the MK5 model
and the X-ray structures of MK2 and MK3 using the
approach as for compounds 8 and 11.
Results
Biochemical studies of DAs against MK5
Diterpenoid alkaloids were reported as moderate to potent
inhibitors of the bifunctional copper containing enzyme
tyrosinase [35]. This prompted us to test whether they
could inhibit the activity of protein kinases. MK5, which
belongs to the group of calcium/calmodulin-dependent
protein kinases [58] was selected as a target. To ensure a
clear potential inhibition, high concentrations (2 mM) were
initially tested. The ﬁrst screening of different natural and
semisynthetic DAs (structures shown in Fig. 7, see below,
under ‘‘Docking of inhibitors at the ATP binding site of
MK5’’) displayed inhibitory activity of all examined
compounds (Fig. 1). Three of the compounds, aconitine
(6), aconine (8) and noroxoaconitine (11) completely
blocked MK5 enzyme activity at the tested concentration.
Next, we performed dose–response studies using mul-
tiple concentrations of compounds 8 and 11, and
determined the IC50 values. While the IC50 value for
compound 8 was in the mM range, compound 11 had an
IC50 of 37.5 lM (data not shown). These results demon-
strate that compound 11 is a more potent MK5 inhibitor
than compound. 8.
DA compounds prevent PKA-induced nuclear export
of MK5
MK5 contains nuclear export signal (NES) and nuclear
localization signal (NLS) motifs, i.e., sequences that
Fig. 1 Initial screening of some
diterpenoid alkaloids (DAs) for
their inhibitory activity towards
MK5. The percent inhibition of
MK5 kinase activity by
compounds 1, 3, 4, 6, 8, 11, and
13 at concentration of 2 mM
was tested. The activity of MK5
towards the PRAKtide substrate
in the absence of inhibitor was
arbitrary set as 100% and the
residual activity in the presence
of inhibitor was related to this.
These values then allowed us to
calculate the percentage of
inhibition
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nucleus, respectively. Due to these signals, MK5 shuttles
between the nucleus and the cytoplasm in a cell. In resting
cells, MK5 resides predominantly in the nucleus [59, 60].
Recently, we reported transient nuclear export of MK5 in
the presence of active cAMP-dependent protein kinase
(PKA) or when overexpressing the catalytic subunit Ca of
PKA in PC12 cells. This process requires the kinase
activity of both Ca and MK5 as a kinase dead Ca could not
trigger nuclear export of MK5, while activation of the
cAMP/PKA pathway failed to induce nucleocytoplasmic
redistribution of kinase dead MK5 [29]. Hence, we rea-
soned that inhibition of the MK5 activity by compound 11
would prevent PKA-induced nuclear export of MK5.
EGFP-MK5-transfected cells were left untreated or
exposed to 20 lM of compound 11. This concentration was
not toxic for the cells (results not shown). Cells were
subsequently exposed to the cAMP-elevating agent for-
skolin, and the subcellular distribution of EGFP-MK5 was
monitored by confocal microscopy. Thirty minutes after
treatment with forskolin, approximately 84% cells that did
not receive DA compound 11 displayed both nuclear and
cytosolic EGFP-MK5 (Fig. 2b) versus 6% in untreated
control cells (Fig. 2a). Pretreatment with compound 11 at a
concentration of 20 lM reduced cAMP/PKA-induced
nuclear export of MK5 to 20% (Fig. 2c). To exclude that
the effect of this compound on the subcellular behavior of
MK5 was a result of inhibiting the nuclear export
machinery and not the kinase activity, we compared the
subcellular localization of the EGFP-NES-MK5 T182A
fusion protein in the absence and presence of compound
11. The mutation T182A destroys the kinase activity of
MK5 but also makes MK5 unable to shuttle to the
cytoplasm. Fusing a functional NES from human immu-
nodeﬁciency virus Rev protein causes EGFP-NES-MK5
T1882A to reside exclusively in the cytoplasm. So this
EGFP-MK5 mutant is a kinase dead MK5 that resides
solely in the cytoplasm. Compound 11 did not interfere
with the cytoplasmic localization of EGFP-NES-MK5
T182A, indicating that this compound had no effect on the
nuclear export machinery (compare panels d and e in
Fig. 2). The results suggest that compound 11 does not
prevent PKA-induced nuclear export of MK5 by interfering
with the nuclear export machinery, but rather by inhibiting
the catalytic activity of MK5.
Compound 8 and 11 are ATP but not substrate
competitors
Many of the known protein kinase inhibitors act through
competition with ATP for binding to the ATP binding
pocket of the enzyme [61]. Enzyme inhibitor kinetic
reactions were performed to study the kinetic trends and
competitions between the compounds (11 and 8) and ATP.
Fig. 2 Noroxoaconitine (compound 11) prevents PKA-induced
nucleocytoplasmic translocation of MK5. a EGFP-MK5 transfected
cells in the absence of forskolin and compound 11. b As in (a), but
EGFP-MK5 subcellular localization was monitored 30 min after the
cells were exposed to 10 lM forskolin. Forskolin treatement resulted
in nuclear and cytoplasmic distribution of MK5 in 84% of the
examined cells. c As in (b), but cells were pretreated with 20 lMo f
compound 11. d Cells transfected with EGFP-NES-MK5 T182A. e As
in (d), but cells were treated with 20 lM of compound 11. The
subcellular location of ectopic expressed EGFP-MK5 and EGFP-
NES-MK5 T182A fusion proteins was monitored by EGFP ﬂuores-
cence (green channel) in a confocal microscope
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0.146 mM. Enzyme kinetic studies of compounds 8 and 11
against varying ATP concentrations showed that both act
on MK5 in an ATP-competitive manner and their Ki values
were calculated to be 301.0 and 0.675 lM, respectively.
These results may indicate that they bind at the ATP
binding site of MK5, and conﬁrm that compound 11 is a
more potent MK5 inhibitor than compound 8. The
Lineweaver–Burk plots of compound 11 (panel a) and
compound 8 (panel b) against ATP are shown in Fig. 3.
Dose-dependent studies with increasing concentrations of
PRAKtide substrate showed that compound 11 did not
interfere with the binding of the substrate (results not
shown). Taken together, our results indicate that compound
11 acts as a competitor of ATP binding.
Compound 11 abrogates MK3- and MK5-,
but not MK2-mediated phosphorylation of Hsp27
Because MK2 and MK3 are most similar to MK5, we
wanted to test the effect of compound 11 on the kinase
activities of MK2 and MK3. The small heat shock protein
Hsp27 has been shown to be an in vitro and in vivo sub-
strate for all three kinases [62], and thus we monitored their
ability to phosphorylate recombinant Hsp27 at the relevant
serine residue 78 in presence or absence of this compound.
These studies showed that compound 11 did not interfere
with MK2-mediated phosphorylation of Hsp27 (compare
lanes 5 and 6 in Fig. 4), but it almost completely ablated
phosphorylation by MK5 and MK3 [compare lanes 1 and 2
(MK5) with lanes 3 and 4 (MK2) in Fig. 4].
Fig. 3 Compounds 8 and 11 are
ATP binding competitors.
Enzyme kinetic models of
compounds 11 and 8 against
increasing concentrations of
ATP. The Lineweaver–Burk
plots of compound 11 (a) and
compound 8 (b) against ATP
Fig. 4 Compound 11 inhibits
Hsp27 phosphorylation by MK3
and MK5, but not by MK2.
Recombinant Hsp27 was
incubated with puriﬁed MK2,
MK3, or MK5 in the presence or
absence of compound 11. Hsp27
phosphorylation at serine
residue 78 (p-Ser78 Hsp27) was
monitored by western blot with
phosphoserine-78 speciﬁc
antibodies. Lanes 1, 3, and 5:
Hsp27 incubated with puriﬁed
MK5, MK3, and MK2,
respectively. Lanes 2, 4, and 6:
as lanes 1, 3, and 5 but in the
presence of 20 lM
noroxoaconitine (compound 11)
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Three-dimensional (3D) X-ray crystal structures of MK2
apoenzyme, truncated and point mutated forms, and of
MK2 in complex with p38
MAPK, ADP, AMPPNP, or
staurosporine have been published [57, 63–65]. Recently,
an X-ray structure of MK3 in complex with the pharma-
ceutical lead compound P4O was also published [54]. In
the absence of an available X-ray crystal structure of MK5,
we constructed a three-dimensional (3D) model of MK5 by
homology with MK2 and MK3 using the homology
modeling approach. Multiple sequence alignments using
ClustalW [66, 67], showed that MK5 has 43% amino acid
sequence identity with MK2 (PDB id: 2OZA) [43], and
41% amino acid sequence identity with MK3 [54]. The
structure of MK2 (2OZA) was therefore used as a template
for constructing a 3D model of MK5 (Fig. 5).
The structural quality of the model was checked and
compared with the template structure (MK2). The Rama-
chandran plot of the model (panel b of Fig. 5) revealed that
88.7% of the residues were in most favored regions, which
is better than the template X-ray structure (86.9%).
Fig. 5 Multiple sequence
alignment and the homology-
based model of MK5. a The
primary sequence alignments of
MK5 (accession number
NP_003659), MK2 (chain A of
2OZA), and MK3 (accession
number NP_849238) are shown
and identical residues are
indicated with asterisks in the
consensus, while analogous
residues are shown by colons.
The conserved GXGXXG motif
is located at the N-terminal part
of the proteins. b Ramachandran
plot of the MK5 model. c The
superimposition of the template
(2OZA) and the MK5 model
(RMSD value of 0.68 A ˚)
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averaged 3D–1D score of more than 0.2, whereas the
corresponding value for the template was 82%. During the
assessment of PROVE scores for both the model and
template, the mean Z score was found to be 0.086 and
0.278, respectively, which also indicates a structurally high
quality model.
Finally, the 3D MK5 model was superimposed onto the
3D structure of the template 2OZA (shown in panel c of
Fig. 5), giving a RMSD of 0.68 A ˚ between backbone Ca
atoms of template and model. The structural deviations
between the model and the template were mainly seen in
some loop regions, but secondary structure elements (not
shown) and the ATP binding site (GXGXXG) were highly
conserved (Fig. 5).
Docking of inhibitors at the ATP binding site of MK5
Prior to docking, putative binding pockets at the MK5
model were predicted using the ‘pocket ﬁnder’ algorithm
of ICM. The best predicted binding pocket is shown in
panel a of Fig. 6, and corresponds to the ATP binding
pocket of MK2 and MK3. The predicted binding pocket
included the following amino acids of MK5: Leu28, Ile32,
Gly34, Val36, Ala49, Lys51, Ile32, Gly34, Val36, Ala49,
Lys51, Met102, Met105, Glu152, Asn153, Leu155, Cys168
and Asp169. The enzyme kinetic studies indicated that
compounds 8 and 11 are ATP competitive, and they were
therefore docked into the predicted binding pocket of MK5
that corresponds to the ATP binding pocket of MK2 and
MK3. Docking poses were evaluated based on docking
energy, ligand conformation and similarities with ATP
binding in known X-ray structure complexes. The highest
scored docking complex of compound 8 had a docking
energy of -72.26 kcal/mol, while the binding energy (DG)
was calculated to -0.89 kcal/mol. For compound 11, the
highest scored docking pose (panels c and d of Fig. 6)
showed a binding mode very similar to the ATP binding in
the X-ray structure complex of MK2 with ATP (PDB code:
2PHK [56]). The docking energy of compound 11 was
-90.4 kcal/mol, while (DG) was calculated to -9.0 kcal/
mol, indicating that compound 11 binds more strongly to
MK5 than compound 8.
Finally, the docked complexes of both compounds were
superimposed and their binding modes compared. The
RMSD between identical parts of their structure was 0.2 A ˚
(shown in panel d of Fig. 6). The major difference between
the binding modes of the compounds was due to the
presence of a phenyl ring in compound 11 lacking in
compound 8 (see Fig. 7), which probably plays a major
role of the inhibitory activities against MK5. The phenyl
ring of compound 11 interacted with MK5 in a quite
hydrophobic region of the binding pocket consisting of
Leu28, Ala49, Met102, Met105 and Leu155 (Fig. 6).
The docking indicated that compound 8 has several
hydrophobic interactions with amino acids in the ATP
binding pocket. Leu28, Gly29, Gly31 Leu155 and Met105
of MK5 all interacted with compound 8 after docking.
Fig. 6 Docking of compound
11 at the ATP binding site of
MK5. a The predicted binding
pocket of MK5 which
corresponds to the ATP binding
site of MK2 and MK3; b,c the
best docking pose of compound
11; d superimposition of the
compound 11 (in dark-blue stick
model) and 8 (in dark-yellow
stick model) in their best
docking poses
296 S. Kostenko et al.A hydroxyl oxygen of compound 8 formed a hydrogen
bond with a side chain oxygen of Asp169. The hydroxyl
group of compound 11 (Fig. 7) had a hydrogen bond with
the backbone carbonyl oxygen of Glu152. Compound 11
also formed a hydrogen bond with the backbone carbonyl
group of Leu28.
Compound 11 was also docked into the ATP binding
sites of the X-ray structure of MK2 (PDB id: 2OZA) [43]
and MK3 [54]. The docking indicated that compound 11
may bind both MK2 and MK3, but with weaker afﬁnity
than for MK5. The docking energy for MK2 was
-79.1 kcal/mol, while the calculated binding energy was
Fig. 7 2D molecular structures of the DAs screened against MK5
Noroxoaconitine inhibits Mapkap kinase 5 (MK5) 297-5.2 kcal/mol. The corresponding values for MK3 were
-72.1 kcal/mol and -4.2 kcal/mol, respectively.
To validate our docking procedure, the potent inhibitor
of MK2, MK3 and MK5 2-(2-quinolin-3-ylpyridin-4-yl)-
1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one was
docked into the ATP binding pockets of MK2, and MK3
and the predicted pocket of the MK5 model. This inhibitor
has IC50 values of 0.008.5 lM for MK2, 0.21 lM for MK2
and 0.081 lM for MK5 [68]. The calculated binding
energies(DG)forMK2,MK3andMK5were-10.3 kcal/mol,
-3.8 kcal/mol and -7.3 kcal/mol, respectively. The
DG and the IC50 values were compared using linear
regression and found to be highly correlated (R
2 = 0.93).
The calculated binding energy (DG) of compound 11 is
overestimated compared with the experimental observa-
tion. Compound 11 contains functional groups with strong
hydrogen bonding capacity, and a reason for the overesti-
mations may be imperfect parameterization of these
reactive groups. However, the results obtained for the
potent binder 2-(2-quinolin-3-ylpyridin-4-yl)-1,5,6,7-tetra-
hydro-4H-pyrrolo[3,2-c]pyridine-4-one show the validity
of our docking approaches.
Discussion
Protein kinases, including protein kinases of the MAP
kinase pathways are attractive therapeutic targets for
development of speciﬁc inhibitors because they often dis-
play perturbed activity in clinical conditions such as
cancer, cardiac conditions, neurological and inﬂammatory
diseases [69–72]. The search for highly speciﬁc MAP
kinase inhibitors is therefore a major challenge for phar-
maceutical companies. Unfortunately, many of the protein
kinase inhibitors developed today display little speciﬁcity
and have therefore not entered the clinic [73–75].
MK5 is a compound of the MAP kinase pathways, but
studies aimed at elucidating the role of MK5 have been
hampered by the lack of a speciﬁc inhibitor. DAs are a
group of complex plant chemicals with similar structure to
that of terpene. A large number of these alkaloids were
isolated from Aconitum, Delphinium and Consolida. The
DAs demonstrate plethora of pharmacological properties,
such as analgesic, anti-arrhythmic, anti-inﬂammatory,
arrhythmogenic, curariform, hypotensive, local anesthetic,
neurotropic, psychotropic, and spasmolytic (reviewed in
[36, 76, 77]). Therefore, we investigated whether they
possess the potential to inhibit MK5. Our screening showed
that some of the DAs can suppress the catalytic activity of
MK5. Of the tested compounds, noroxoaconitine (com-
pound 11) displayed the strongest MK5 inhibition with
an IC50 = 37.5 lM, and a very favorable interaction
energy predicted by docking studies. The IC50 value is in
the same range as that of the two previously described
unspeciﬁc MK5 inhibitors: epigallocatechin gallate (EGCG)
from green tea (IC50\10 lM) and ﬂavokavain A
(IC50 = 10 lM) from kava (Piper methysticum)[ 74, 78].
In accordance with ﬂavokavain A, noroxoaconite inhibited
MK5 and MK3 kinase activity, but had no effect on MK2
[78]. The effect of EGCG on the enzymatic activity of
MK2 and MK3 was not tested [74]. Both EGCG and ﬂa-
vokavain, however, are rather unspeciﬁc. EGCG at a
concentration of 10 lM was shown to inhibit the in vitro
kinase activity, by *90%, of ERK2, DYRK1A, ROCK-II,
and PDK1 [74]. The same concentration of ﬂavokavain A
also inhibited the protein kinases Aurora B, DYRK1A,
IKKb, and MK3 more or to a similar extent, while
approximately 40–70% inhibition was measured for ERK8,
GSK3b, RSK2, MK2, MSK1, p70
S6K, PDK1, PHK, PKA,
PKB2, PLK1, p38d, and smMLCK [78]. While our studies
suggest that 20 lM noroxoaconitine can inhibit the kinase
activity of MK5 in cells, the effect of EGCG and ﬂa-
vokavain on MK5 in vivo has not been investigated.
The theoretical docking studies indicated that nor-
oxoaconite ﬁtted nicely into the ATP binding pocket of
MK3 and MK5 in agreement with the experimental studies.
The docking indicated that noroxoaconite binds a bit dif-
ferently in MK3 and MK5. In MK3, the phenyl ring of
noroxoaconite binds in between Leu52 in a b-sheet region,
and Glu172 located four amino acids C-terminal of the
catalytic RD region. In MK5, the phenyl ring of nor-
oxoaconite interacted in a quite hydrophobic region of the
binding pocket consisting of Leu28, Ala49, Met102,
Met105 and Leu155 (Fig. 6). In MK5, a more bulky region
of the inhibitor interacts inbetween Ala30 and Glu152 that
corresponds to Leu52 and Glu172 in MK3. The main
reason for the differences in orientation seems to be that the
cleft between Leu52 and Glu172 in MK3 is much narrower
than the corresponding cleft between Ala30 and Glu152 in
MK5. The atomic distance between the Ca-atoms of Leu52
and Glu172 in MK3 is 8.6 A ˚, while the corresponding
distance between Ala30 and Glu152 in MK5 is 12.1 A ˚,
which might explain our docking predictions indicating
that noroxoaconite interacts with MK3 with the phenylring
inbetween Leu52 and Glu172, while it interacts with MK5
with a more bulky region between Ala30 and Glu152.
The experimental studies showed that noroxoaconite did
not prevent MK2-mediated phosphorylation of recombi-
nant Hsp27 at serine residue 78. However, this was not
predicted by the docking studies since noroxoaconite
bound MK2 similar to the binding mode in MK5. At
present, we cannot explain the speciﬁcity of compound 11
for MK3 and MK5, but ﬂavokavain A also inhibited
MK3 and MK5, but not MK2, despite the higher degree
of overall identity between MK2 and MK3 than
between MK3 and MK5 [55]. Similarly, the MK2 inhibitor
298 S. Kostenko et al.2-(2-quinolin-3-ylpyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyr-
rolo[3,2-c]pyridin-4-one (IC50 = 8.5 nM) is a more potent
inhibitor for MK5 (IC50 = 81 nM) than for MK3 (IC50 =
210 nM), even though the ATP binding pockets of MK2
and MK3 show most identity [68].
Inanefforttodeterminethespeciﬁcityofnoroxoaconite,a
screen was performed by the company ProQinase (Freiburg,
Germany)with25 lMofthiscompoundagainst252different
proteinkinases.Whilesigniﬁcantinhibitionofonlytwoother
proteinkinaseswasdetected(GRK2andS6Kb),noinhibition
was found for MK3 and MK5 (see Electronic supplementary
material, Table S1). At present, we cannot explain why this
company failed to detectinhibition of MK5, while we clearly
observed an inhibition using different experimental approa-
ches. Differences in assay, source of MK5, conditions, and
substrate may account for this discrepancy. While we used
Praktide or Hsp27 as speciﬁc substrates for MK5, ProQinase
usedthe peptideRBER-CHKtide,whichwasalsousedfor 56
other protein kinases in their screen.
In conclusion, we have identiﬁed a potent novel MK5
inhibitor, noroxoaconitine (compound 11), which most
probably acts by competing with ATP for the ATP binding
pocketintheenzyme.NoroxoaconitinealsoreducedMK3but
not MK2 kinase activity towards Hsp27 in vitro. As MK3 is
less expressed and less active than MK2 [22], the use of this
inhibitor may allow testing the individual involvement of
MK2andMK5incellularresponsestostresswhichare know
toactivatebothenzymes[15].Rationallydesignedderivatives
of noroxoaconitine may then be synthesized and experimen-
tally tested for their potency and speciﬁcity to inhibit MK5,
andmayenableustoelucidatethebiologicalrolesofMK5.In
addition, such inhibitors may prove therapeutic values in
diseases with aberrant MK5 functions.
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